Drug Trial Radar · NCT07710248
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 11, 2026
Primary completion
May 17, 2027
Study completion May 17, 2027
Sponsor
- Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. The primary objective is to evaluate the safety and efficacy of SG301 SC Injection in participants with ITP, while the secondary objectives are to assess the pharmacokinetic, pharmacodynamic and immunogenicity profiles of SG301 SC Injection in ITP participants. A total of 60 ITP participants are planned to be enrolled in this study and randomly assigned at a 1:1:1 ratio to the low dose group, high dose group and placebo group, with approximately 20 participants per group. All participants enrolled in this study may receive concomitant background therapies at stable doses for at least 4 weeks prior to the first study drug administration, and is expected to be maintained throughout the study period.
Conditions
- Primary Immune Thrombocytopenia
Interventions
low dose groupDrug
SG301 SC weekly for a total of 8 doses, subcutaneous injection
high dose groupDrug
SG301 SC weekly for a total of 8 doses , subcutaneous injection
Placebo groupDrug
SG301 SC Placebo weekly for a total of 8 doses, subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: up to 24 weeks
- ORRTime frame: at Week 8 of treatment
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Liuzhou People's Hospital
Liuzhou, Guangxi, China · Not yet recruiting
Yulin Red Cross Hospital
Yulin, Guangxi, China · Recruiting
Hebei University Affiliated Hospital
Baoding, Hebei, China · Not yet recruiting
Affiliated Hospital of Chengde Medical University
Chengde, Hebei, China · Not yet recruiting
North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, China · Recruiting
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Recruiting
Pingdingshan First People's Hospital
Pingdingshan, Henan, China · Recruiting
Henan Cancer Hospital
Zhenzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Not yet recruiting
Siping Central People's Hospital
Siping, Jilin, China · Recruiting
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
Jinan, Shandong, China · Recruiting
Jining No.1 People's Hospital
Jining, Shandong, China · Recruiting
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China · Recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University
Xian, Shanxi, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Yunnan Provincial First People's Hospital
Kunming, Yunnan, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.